Nyxoah (NASDAQ:NYXH) Announces Earnings Results

Key Points

• Nyxoah reported quarterly earnings of ($0.63) EPS, missing analysts' estimates by ($0.03).
• The company has a negative return on equity of 63.37% and a negative net margin of 1,571.39%.
• Stifel Nicolaus reduced their target price on Nyxoah shares from $15.00 to $14.00 while maintaining a "buy" rating.

Nyxoah (NASDAQ:NYXH - Get Free Report) announced its earnings results on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01), Zacks reports. Nyxoah had a negative return on equity of 79.18% and a negative net margin of 1,541.84%.The company had revenue of $1.58 million for the quarter, compared to analyst estimates of $1.33 million.

Nyxoah Price Performance

Shares of NYXH stock traded up $0.08 during trading hours on Friday, reaching $6.43. 79,931 shares of the company were exchanged, compared to its average volume of 165,693. Nyxoah has a fifty-two week low of $5.55 and a fifty-two week high of $11.87. The stock's fifty day moving average is $7.44 and its two-hundred day moving average is $7.89. The company has a market cap of $219.01 million, a price-to-earnings ratio of -2.80 and a beta of 1.61. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.63 and a quick ratio of 3.35.

Hedge Funds Weigh In On Nyxoah

Several large investors have recently bought and sold shares of NYXH. Shay Capital LLC bought a new position in Nyxoah in the second quarter valued at approximately $374,000. Raymond James Financial Inc. bought a new position in Nyxoah in the second quarter valued at approximately $70,000. Finally, Bank of America Corp DE boosted its stake in Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company's stock valued at $59,000 after acquiring an additional 3,303 shares during the last quarter.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.